학회지

권호별 검색

  • HOME
  • 학회지
  • 학회지
  • 권호별 검색
LETTER TO THE EDITOR
Dementia and Neurocognitive Disorders 2024: 23: 1: 71-73

전문보기

Novel Pathogenic Missense NF1-Variant Associated With Cognitive Impairment
Faheem Arshad , 1 Ashwin Prasad , 1 Aparna Somaraj , 1 Gautham Arunachal Udupi , 2 Subasree Ramakrishnan , 1 Suvarna Alladi 1
1 Department of Neurology, National Institute of Mental Health and Neurosciences (NIMHANS), Bengaluru, India 2 Department of Human Genetics, National Institute of Mental Health and Neurosciences (NIMHANS), Bengaluru, India
Novel Pathogenic Missense NF1-Variant Associated With Cognitive Impairment
Faheem Arshad , 1 Ashwin Prasad , 1 Aparna Somaraj , 1 Gautham Arunachal Udupi , 2 Subasree Ramakrishnan , 1 Suvarna Alladi 1
1 Department of Neurology, National Institute of Mental Health and Neurosciences (NIMHANS), Bengaluru, India 2 Department of Human Genetics, National Institute of Mental Health and Neurosciences (NIMHANS), Bengaluru, India
Dear Editor,
Early-onset dementia (EOD) is a clinically heterogenous disorder, accounting for 1%–2%
of all dementia cases, before 65 years of age.1
Genetic factors play a crucial role. About
16%–30% cases can be diagnosed with whole exome sequencing.2
The unique ancestry and
genetic makeup of South Asians make it challenging to understand novel variants. The NF1
gene, which encodes neurofibromin protein, is the main cause of dominantly inherited
neurofibromatosis type 1 (NF1).3
Cognitive deficits can occur throughout the lifespan.4
The
frequency and cognitive phenotype associated with NF1 the variant are not well understood
yet due to early mortality linked to the variant. Herein, we describe and highlight unusual
clinical and imaging characteristics of a patient with dementia having a variant of NF1.
A 50-year-old right-handed woman presented to our clinic with 18 months of behavioral
disturbances including apathy, social withdrawal, lack of personal hygiene, and emotional
lability. Subsequently, she developed difficulty in dressing and handling finances. Within 6
months of her first visit, her speech became worse. She became completely dependent for
daily activities. Her medical history was notable for an episode of sudden onset giddiness
without any loss of consciousness lasting 5 minutes 2 years ago. There was no family
history of similar illness or any psychiatric, motor, or memory problems (Fig. 1). Systemic
examination was unremarkable. Her Addenbrooke’s Cognitive Examination III score was
56/100 (normal ≥87/100). Her individual cognitive domain scores were: attention, 10/18;
memory, 16/26; fluency, 6/14; language, 20/26; and visuospatial, 4/16. Her cognitive profile
showed impaired attention, reduced spontaneous speech, impaired phonemic fluency,
and visuo-construction skills (Fig. 1). Her lower limbs (right > left), brisk reflexes, extensor
planters, and elicitable primitive reflexes showed asymmetric rigidity.
Laboratory investigations to rule out treatable cause of dementia were normal. Brain
magnetic resonance imaging (MRI) (Fig. 1) showed multiple lacunar infarcts and
microbleeds, with T2/fluid-attenuated inversion recovery (FLAIR) hyperintensities in
bilateral basal ganglia, thalami, and subcortical locations of bilateral cerebral hemispheres
and cerebellum. 18-Fluorodeoxyglucose positron emission tomography MRI brain provided
further evidence of hypometabolism in basal ganglia, thalami, and right frontoparietal
regions. As the patient was diagnosed to have EOD, genetic analysis in form of whole exome
sequencing was performed. A novel pathogenic missense variant in exon 45 of NF1 gene at position c.6764A>C (p.Glu2255Ala) in a heterozygous state was identified. The variant has
a low rate of benign missense variation. It is predicted to be a damaging variant by both
SIFT and polyPhen2. Based on these, this variant was classified as likely pathogenic per the
American College of Medical Genetics and Genomics recommendations.5
The patient was
diagnosed with vascular cognitive impairment associated with pathogenic NF1 variant. She
is managed with symptomatic medications and cognitive stimulation therapy. Only one
patient among 105 patients diagnosed with dementia in our Cognitive Disorders Clinic who
underwent whole exome sequencing showed this NF1 variant.
The NF1 gene is a negative regulator for RAS signaling. It has variable expressivity, penetrance,
and mosaicism, making it difficult to diagnose, especially for those without a family history.
Possible explanations include NF1 gene heterogeneity, modifiers, epigenetic regulators,
and environment factors like hormones and vitamin D.6
It primarily affects the peripheral
nervous system, the central nervous system, the skin, the skeletal system, and the vascular
systems.3
Children are more often affected by neurofibromatosis than adults. They experience
cognitive and behavior problems, including impaired general cognition, attention, reasoning,
abstract knowledge, visuo-constructive skills and language disturbances, especially poor
reading skills.7
Deficits in executive function and auditory long-term memory have also been
reported.8
Visuospatial skills are considered hallmark deficits in patients with NF1,8
while very
little is known about auditory memory functions of such patients.
The association between NF1 and dementia has not been confirmed. However, a Finnish
cohort has found an increased risk for dementia among individuals with NF1 compared
to controls.3
This is attributed to mosaicism, highlighting the phenotypic heterogeneity
observed in patients with NF1 variants. Brain imaging revealed that our patient might have
an NF1 variant-related vascular disease, which could cause aneurysms. Microaneurysms
are formed in the deep grey matter due to lacunar infarcts. Neuroimaging studies of NF1 patients have observed specific findings such as unidentified bright objects (UBOs), which
are hyperintensities on T2-weighted or FLAIR without mass effect or contrast enhancement.
These were seen in 70% of NF1 patients. They could be diffuse or discrete.9
However, no
robust link has been found between major cognitive deficits in NF1 and UBOs.
Reverse phenotyping is crucial for identifying rare pathogenic variants as seen in
our patient with dementia. Identification of such variants will potentially lead to the
development of personalized therapeutic interventions. Genome editing technology holds
significant potential for innovative and transformative treatments. However, existing
research is insufficient to fully comprehend the roles of genotypes, phenotypes, and
genetic heterogeneity in patients with dementia with NF1 variant. Further research studies
with functional studies and advanced imaging are required to better understand novel
mechanisms and neural basis of patients with dementia with NF1 variant.
Key Words: